Literature DB >> 2416953

Carbohydrate side chains of Rauscher leukemia virus envelope glycoproteins are not required to elicit a neutralizing antibody response.

J H Elder, J S McGee, S Alexander.   

Abstract

Antisera raised against Rauscher leukemia virus (R-MuLV) contain a preponderance of antibodies against glycoprotein gp70 that are dependent on the presence of carbohydrate side chains for reactivity, as judged by immunoprecipitation or Western blotting. However, the majority of neutralizing antibodies were not dependent on the presence of carbohydrate, as indicated by (i) the ability of deglycosylated R-MuLV to adsorb neutralizing antibody from sera as efficiently as glycosylated R-MuLV and (ii) the ability of deglycosylated R-MuLV to induce neutralizing antibody responses when injected into rabbits. Moreover, a faster response was obtained with deglycosylated R-MuLV than with untreated control virus in the latter experiments. The results indicate that the neutralizing antibodies are a discrete subpopulation of the total antibody response. Furthermore, the carbohydrate moieties appear to afford protection to the virion during infection, rather than serve as a target for neutralization.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2416953      PMCID: PMC252732     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  13 in total

1.  Membrane receptors for murine leukemia viruses: characterization using the purified viral envelope glycoprotein, gp71.

Authors:  J DeLarco; G J Todaro
Journal:  Cell       Date:  1976-07       Impact factor: 41.582

2.  Antigenic reactivity of a soluble glycoprotein associated with bovine leukemia virus.

Authors:  M J Schmerr; J M Miller; M J Van Der Maaten
Journal:  Virology       Date:  1981-03       Impact factor: 3.616

Review 3.  Mammalian C-type oncornaviruses: relationships between viral structural and cell-surface antigens and their possible significance in immunological defense mechanisms.

Authors:  W Schäfer; D P Bolognesi
Journal:  Contemp Top Immunobiol       Date:  1977

4.  endo-beta-N-acetylglucosaminidase F: endoglycosidase from Flavobacterium meningosepticum that cleaves both high-mannose and complex glycoproteins.

Authors:  J H Elder; S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

5.  Radiommunoassays for the 70,000-molecular-weight glycoproteins of endogenous mouse type C viruses: viral antigen expression in normal mouse tissues and sera.

Authors:  S Hino; J R Stephenson; S A Aaronson
Journal:  J Virol       Date:  1976-06       Impact factor: 5.103

6.  Role of carbohydrate in biological functions of Friend murine leukemia virus gp71.

Authors:  W Schäfer; P J Fischinger; J J Collins; D P Bolognesi
Journal:  J Virol       Date:  1977-01       Impact factor: 5.103

7.  A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody.

Authors:  J J Skehel; D J Stevens; R S Daniels; A R Douglas; M Knossow; I A Wilson; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

8.  Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens.

Authors:  S Alexander; J H Elder
Journal:  Science       Date:  1984-12-14       Impact factor: 47.728

9.  O-linked oligosaccharides of mouse egg ZP3 account for its sperm receptor activity.

Authors:  H M Florman; P M Wassarman
Journal:  Cell       Date:  1985-05       Impact factor: 41.582

10.  Carbohydrate specificity of sea urchin sperm bindin: a cell surface lectin mediating sperm-egg adhesion.

Authors:  C G Glabe; L B Grabel; V D Vacquier; S D Rosen
Journal:  J Cell Biol       Date:  1982-07       Impact factor: 10.539

View more
  9 in total

1.  Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1.

Authors:  W R Lee; W J Syu; B Du; M Matsuda; S Tan; A Wolf; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Topological and operational delineation of antigenic sites on the HN glycoprotein of Newcastle disease virus and their structural requirements.

Authors:  K Nishikawa; T Morishima; T Toyoda; T Miyadai; T Yokochi; T Yoshida; Y Nagai
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

Review 3.  Carbohydrates as antigenic determinants of glycoproteins.

Authors:  T Feizi; R A Childs
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

4.  Posttranslational modifications distinguish the envelope glycoprotein of the immunodeficiency disease-inducing feline leukemia virus retrovirus.

Authors:  M L Poss; J I Mullins; E A Hoover
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

5.  Inhibition of type 5 adenovirus infectivity by periodate oxidation.

Authors:  G Ogier; Y Michal; V Thomas; G Quash; J D Rodwell
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

6.  Site-directed serology with synthetic peptides representing the large glycoprotein G of respiratory syncytial virus.

Authors:  E Norrby; M A Mufson; H Alexander; R A Houghten; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

7.  A comparison of T cell responses to glycoprotein B (gB-1) of herpes simplex virus type 1 and its non-glycosylated precursor protein, pgB-1.

Authors:  C A O'Donnell; W L Chan
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

8.  Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.

Authors:  A Benjouad; J C Gluckman; L Montagnier; E Bahraoui
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

9.  Localization of neutralizing regions of the envelope gene of feline leukemia virus by using anti-synthetic peptide antibodies.

Authors:  J H Elder; J S McGee; M Munson; R A Houghten; W Kloetzer; J L Bittle; C K Grant
Journal:  J Virol       Date:  1987-01       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.